Factors associated with recently acquired hepatitis C virus infection in people who inject drugs in England, Wales and Northern Ireland: new findings from an unlinked anonymous monitoring survey

SUMMARY Monitoring infections and risk in people who inject drugs (PWID) is important for informing public health responses. In 2011, a novel hepatitis C antibody (anti-HCV) avidity-testing algorithm to identify samples compatible with recent primary infection was introduced into a national surveillance survey. PWID are recruited annually, through >60 needle-and-syringe programmes and prescribing services. Of the 980 individuals that could have been at risk of HCV infection, there were 20 (2%) samples that were compatible with recent primary infection. These were more common among: those imprisoned ⩾5 times [8/213; adjusted odds ratio (aOR) 8·7, 95% confidence interval (CI) 2·04–37·03]; women (8/230; aOR 3·8, 95% CI 1·41–10·38); and those ever-infected with hepatitis B (5/56; aOR 6·25, 95% CI 2·12–18·43). This study is the first to apply this algorithm and to examine the risk factors associated with recently acquired HCV infection in a national sample of PWID in the UK. These findings highlight underlying risks and suggest targeted interventions are needed.

[1]  S. Hutchinson,et al.  A hepatitis C avidity test for determining recent and past infections in both plasma and dried blood spots. , 2013, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[2]  C. Stoicescu,et al.  Developing Effective Health Interventions for Women Who Inject Drugs: Key Areas and Recommendations for Program Development and Policy , 2012, Advances in preventive medicine.

[3]  J. Parry,et al.  The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. , 2011, Addiction.

[4]  H. Wand,et al.  Gender differences in hepatitis C antibody prevalence and risk behaviours amongst people who inject drugs in Australia 1998-2008. , 2010, The International journal on drug policy.

[5]  M. Farrell,et al.  Meta-analysis of drug-related deaths soon after release from prison , 2010, Addiction.

[6]  C. Gaudy-Graffin,et al.  Use of an Anti-Hepatitis C Virus (HCV) IgG Avidity Assay To Identify Recent HCV Infection , 2010, Journal of Clinical Microbiology.

[7]  J. Parry,et al.  Incidence of hepatitis C in drug injectors: the role of homelessness, opiate substitution treatment, equipment sharing, and community size , 2009, Epidemiology and Infection.

[8]  J. Parry,et al.  Prevalence and incidence of hepatitis C in injecting drug users attending genitourinary medicine clinics , 2008, Epidemiology and Infection.

[9]  J. Parry,et al.  Diagnosis of acute hepatitis C virus infection and estimated incidence in low‐ and high‐risk English populations , 2008, Journal of viral hepatitis.

[10]  J. Parry,et al.  Assays for the detection of recent infections with human immunodeficiency virus type 1. , 2008, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[11]  M. Abou-Saleh,et al.  The effectiveness of behavioural interventions in the primary prevention of Hepatitis C amongst injecting drug users: a randomised controlled trial and lessons learned , 2008, Harm reduction journal.

[12]  E. Pontali,et al.  Prevalence of Hepatitis B virus and/or Hepatitis C virus co-infections in prisoners infected with the Human Immunodeficiency Virus. , 2008, International journal of prisoner health.

[13]  R. Coutinho,et al.  Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users , 2007, Addiction.

[14]  M. Busch,et al.  Distinguishing Acute from Chronic and Resolved Hepatitis C Virus (HCV) Infections by Measurement of Anti-HCV Immunoglobulin G Avidity Index , 2007, Journal of Clinical Microbiology.

[15]  J. Kaldor,et al.  High hepatitis C incidence in new injecting drug users: a policy failure? , 2007, Australian and New Zealand journal of public health.

[16]  J. Parry,et al.  Human Immunodeficiency Virus (HIV) Antibody Avidity Testing To Identify Recent Infection in Newly Diagnosed HIV Type 1 (HIV-1)-Seropositive Persons Infected with Diverse HIV-1 Subtypes , 2006, Journal of Clinical Microbiology.

[17]  Rohan Jayasuriya,et al.  Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. , 2006, Addiction.

[18]  J. Parry,et al.  HIV prevalence among injecting drug users in England and Wales 1990 to 2003: evidence for increased transmission in recent years , 2005, AIDS.

[19]  J. Parry,et al.  Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study , 2004, BMJ : British Medical Journal.

[20]  B. Jalaludin,et al.  Risk behaviors and antibody hepatitis B and C prevalence among injecting drug users in south‐western Sydney, Australia , 2004, Journal of gastroenterology and hepatology.

[21]  J. Tang,et al.  Failure to diagnose recent hepatitis C virus infections in London injecting drug users , 2004, Journal of medical virology.

[22]  J. Rich,et al.  Hepatitis C infection and incarcerated populations , 2004 .

[23]  J. Parry,et al.  Evaluation of a modified commercial assay in detecting antibody to hepatitis C virus in oral fluids and dried blood spots , 2003, Journal of medical virology.

[24]  J. Barry,et al.  Retrospective cohort study examining incidence of HIV and hepatitis C infection among injecting drug users in Dublin , 2003, Journal of epidemiology and community health.

[25]  D. Vlahov,et al.  Does Bleach Disinfection of Syringes Protect Against Hepatitis C Infection Among Young Adult Injection Drug Users? , 2002, Epidemiology.

[26]  J. Montaner,et al.  Opportunities for prevention: Hepatitis C prevalence and incidence in a cohort of young injection drug users , 2002, Hepatology.

[27]  M. Schechter,et al.  Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection , 2022 .

[28]  S. Hutchinson,et al.  A method to detect the incidence of hepatitis C infection among injecting drug users in Glasgow 1993-98. , 2001, The Journal of infection.

[29]  J. Parry,et al.  Prevalence of hepatitis C among injection drug users in England and Wales: is harm reduction working? , 2001, American journal of public health.

[30]  J. Parry,et al.  Prevalence of HIV, hepatitis B, and hepatitis C antibodies in prisoners in England and Wales: a national survey. , 2000, Communicable disease and public health.

[31]  R. Dwyer,et al.  Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study , 1998, BMJ.

[32]  J. de Irala,et al.  Reliability of self-reported human immunodeficiency virus risk behaviors in a residential drug treatment population. , 1996, American journal of epidemiology.

[33]  E. Holmes,et al.  Investigation of the pattern of hepatitis C virus sequence diversity in different geographical regions: implications for virus classification. The International HCV Collaborative Study Group. , 1995, The Journal of general virology.

[34]  J. Parry,et al.  HIV infection in injecting drug users attending centres in England and Wales, 1990–1991 , 1993, AIDS.

[35]  J. Parry,et al.  Novel assay for the detection of immunoglobulin G antihuman immunodeficiency virus in untreated saliva and urine , 1993, Journal of medical virology.

[36]  D. Vlahov,et al.  Socially desirable responding and self-reported HIV infection risk behaviors among intravenous drug users. , 1993, Addiction.